Slide background

FROM CANCER RESEARCH TO CURE

Slide background

IMMUNO-ONCOLOGY IS AN AREA OF STRENGTH

Slide background

OUR VISION IS TO IMPROVE THE LIVES OF CANCER PATIENTS

Slide background

OSLO CANCER CLUSTER INNOVATION PARK

PHYSICAL EMBODIMENT OF THE CANCER CLUSTER

Videos

LATEST NEWS

Targovax ASA: Fourth quarter and full year 2016 results

Oslo, Norway, 16 February 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its fourth quarter and full year 2016 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET (details below).

Tweets

MEMBERS OF OSLO CANCER CLUSTER